Centre for Cancer and Inflammation, Barts Cancer Institute, Queen Mary, University of London, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, UK.
Cancer Lett. 2014 Apr 10;345(2):157-63. doi: 10.1016/j.canlet.2013.07.014. Epub 2013 Jul 20.
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal types of cancer with poor prognosis. Despite extensive efforts, the current treatment methods have limited success. Therefore, novel therapeutic approaches are required. The pancreatic tumor microenvironment is rich in growth factors and inflammatory cytokines that support tumor growth, and it is highly immunosuppressive. Up-regulation of cytokine pathways has been shown to modulate PDAC progression and immune evasion; therefore targeting cytokines may have therapeutic benefits. In this review we provide an overview of current understanding of pro- and anti-inflammatory cytokines in pancreatic cancer and their potential as therapeutic targets.
胰腺导管腺癌（PDAC）仍然是预后最差的最致命癌症类型之一。尽管进行了广泛的努力，但目前的治疗方法收效甚微。因此，需要新的治疗方法。胰腺肿瘤微环境富含支持肿瘤生长的生长因子和炎症细胞因子，并且具有高度的免疫抑制性。细胞因子途径的上调已被证明可调节 PDAC 的进展和免疫逃逸；因此，靶向细胞因子可能具有治疗益处。在这篇综述中，我们概述了目前对胰腺癌中促炎和抗炎细胞因子的理解及其作为治疗靶点的潜力。
